Tesofensine vs C-peptide
Head-to-head comparison of Tesofensine (Tesofensine (NS2330)) and C-peptide (Connecting peptide (C-peptide)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Tesofensine | C-peptide |
|---|---|---|
| Category | Weight Management | Pain Management |
| Full Name | Tesofensine (NS2330) | Connecting peptide (C-peptide) |
| Molecular Weight | 426.52 g/mol | 3020.3 Da |
| Half-Life | ~200-300 hours | ~20-30 min |
| Amino Acids | Small molecule | 31 |
| Typical Dose | — | no approved analgesic dose|research-only |
| Route | — | IV|subQ |
| Purity | >98% | ≥98% |
| Studies Count | 35 | 46 |
| Research Status | Phase III Clinical Trials | Pre-clinical |
Tesofensine Benefits
- ✓Potent appetite suppression, increased metabolic rate, enhanced thermogenesis, improved mood during dieting, reduces food reward-seeking behavior
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Tesofensine Dosing
Clinical doses: 0.25-1.0 mg orally once daily. Research typically uses 0.5 mg. Extremely long half-life (8-13 days) means steady-state in 7-10 days.
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Tesofensine Side Effects
- ⚠Dry mouth, insomnia, constipation, increased heart rate, elevated blood pressure. Not recommended with uncontrolled hypertension.
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Research Overview
Tesofensine
Phase II trials showed 12.8 kg average weight loss at 1.0 mg dose over 6 months. Simultaneously inhibits reuptake of norepinephrine, dopamine, and serotonin, producing appetite suppression and increased thermogenesis.
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.